Disease progression in idiopathic pulmonary fibrosis with mild physiological impairment: analysis from the Australian IPF registry

[1]  G. Gokçay,et al.  The quality of sleep in nurses , 2017 .

[2]  A. Hayen,et al.  Baseline characteristics of idiopathic pulmonary fibrosis: analysis from the Australian Idiopathic Pulmonary Fibrosis Registry , 2017, European Respiratory Journal.

[3]  H. Adamali,et al.  A comparison of published multidimensional indices to predict outcome in idiopathic pulmonary fibrosis , 2017, ERJ Open Research.

[4]  Wenbo Tang,et al.  Nintedanib in patients with idiopathic pulmonary fibrosis and preserved lung volume , 2016, Thorax.

[5]  S. Nathan,et al.  Efficacy of pirfenidone in patients with idiopathic pulmonary fibrosis with more preserved lung function , 2016, European Respiratory Journal.

[6]  R. D. du Bois,et al.  Nintedanib in patients with idiopathic pulmonary fibrosis: Combined evidence from the TOMORROW and INPULSIS(®) trials. , 2016, Respiratory medicine.

[7]  R. D. du Bois,et al.  Pirfenidone for idiopathic pulmonary fibrosis: analysis of pooled data from three multinational phase 3 trials , 2016, European Respiratory Journal.

[8]  R. Hubbard,et al.  Global incidence and mortality of idiopathic pulmonary fibrosis: a systematic review , 2015, European Respiratory Journal.

[9]  R. D. du Bois.  6-minute walk distance as a predictor of outcome in idiopathic pulmonary fibrosis , 2014, European Respiratory Journal.

[10]  H. Collard,et al.  Staging of idiopathic pulmonary fibrosis: past, present and future , 2014, European Respiratory Review.

[11]  R. Sussman,et al.  A phase 3 trial of pirfenidone in patients with idiopathic pulmonary fibrosis. , 2014, The New England journal of medicine.

[12]  Joyce S Lee,et al.  A Multidimensional Index and Staging System for Idiopathic Pulmonary Fibrosis , 2012, Annals of Internal Medicine.

[13]  F. Martinez,et al.  Idiopathic pulmonary fibrosis: prognostic value of changes in physiology and six-minute-walk test. , 2006, American journal of respiratory and critical care medicine.

[14]  F. D'Ovidio,et al.  Six-minute-walk distance predicts waiting list survival in idiopathic pulmonary fibrosis. , 2006, American journal of respiratory and critical care medicine.

[15]  G. Raghu,et al.  The timed walk test as a measure of severity and survival in idiopathic pulmonary fibrosis , 2005, European Respiratory Journal.

[16]  A. Nicholson,et al.  Idiopathic pulmonary fibrosis: a composite physiologic index derived from disease extent observed by computed tomography. , 2003, American journal of respiratory and critical care medicine.

[17]  J. Tooze,et al.  Predicting survival in idiopathic pulmonary fibrosis: scoring system and survival model. , 2001, American journal of respiratory and critical care medicine.

[18]  J. Egan,et al.  Pulmonary function in idiopathic pulmonary fibrosis and referral for lung transplantation. , 2001, American journal of respiratory and critical care medicine.

[19]  Efficacy and Safety of Nintedanib in Idiopathic Pulmonary Fibrosis. , 2015, The New England journal of medicine.

[20]  A. Azuma,et al.  A Phase 3 Trial of Pirfenidone in Patients with Idiopathic Pulmonary Fibrosis , 2015 .

[21]  Takeshi Johkoh,et al.  American Thoracic Society Documents An Official ATS / ERS / JRS / ALAT Statement : Idiopathic Pulmonary Fibrosis : Evidence-based Guidelines for Diagnosis and Management , 2011 .

[22]  S. Harari,et al.  Walking distance on 6-MWT is a prognostic factor in idiopathic pulmonary fibrosis. , 2009, Respiratory medicine.

[23]  T. Schaberg,et al.  Lung function tests in patients with idiopathic pulmonary fibrosis. Are they helpful for predicting outcome? , 1997, Chest.